New Insights into Alzheimer’s Disease: Novel Pathogenesis, Drug Target and Delivery
Open Access
- 3 April 2023
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1133
Abstract
Alzheimer’s disease (AD), the most common type of dementia, is characterized by senile plaques composed of amyloid β protein (Aβ) and neurofilament tangles derived from the hyperphosphorylation of tau protein. However, the developed medicines targeting Aβ and tau have not obtained ideal clinical efficacy, which raises a challenge to the hypothesis that AD is Aβ cascade-induced. A critical problem of AD pathogenesis is which endogenous factor induces Aβ aggregation and tau phosphorylation. Recently, age-associated endogenous formaldehyde has been suggested to be a direct trigger for Aβ- and tau-related pathology. Another key issue is whether or not AD drugs are successfully delivered to the damaged neurons. Both the blood–brain barrier (BBB) and extracellular space (ECS) are the barriers for drug delivery. Unexpectedly, Aβ-related SP deposition in ECS slows down or stops interstitial fluid drainage in AD, which is the direct reason for drug delivery failure. Here, we propose a new pathogenesis and perspectives on the direction of AD drug development and drug delivery: (1) aging-related formaldehyde is a direct trigger for Aβ assembly and tau hyperphosphorylation, and the new target for AD therapy is formaldehyde; (2) nano-packaging and physical therapy may be the promising strategy for increasing BBB permeability and accelerating interstitial fluid drainage.Keywords
Funding Information
- National Natural Science Foundation of China (82071214, OJQDSP2022011)
- Fund of Talent Launch Project of Oujiang Laboratory (82071214, OJQDSP2022011)
This publication has 246 references indexed in Scilit:
- Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model TauopathyPLOS ONE, 2013
- Hydrogen sulfide attenuates spatial memory impairment and hippocampal neuroinflammation in beta-amyloid rat model of Alzheimer’s diseaseJournal of Neuroinflammation, 2012
- Trafficking and Proteolytic Processing of APPCold Spring Harbor Perspectives in Medicine, 2012
- Developing β‐secretase inhibitors for treatment of Alzheimer’s diseaseJournal of Neurochemistry, 2011
- Passive Immunization with Anti-Tau Antibodies in Two Transgenic ModelsJournal of Biological Chemistry, 2011
- Vascular β-amyloid and early astrocyte alterations impair cerebrovascular function and cerebral metabolism in transgenic arcAβ miceActa Neuropathologica, 2011
- EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicityProceedings of the National Academy of Sciences, 2010
- Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled TrialJAMA, 2009
- Diffusion in Brain Extracellular SpacePhysiological Reviews, 2008
- Differential Regulation of Dynein and Kinesin Motor Proteins by TauScience, 2008